11 results
8-K
EX-99.1
yp1yhqjz 0ly
7 Nov 22
Verve Therapeutics Provides Regulatory Update on VERVE-101 Investigational New Drug Application and Reports Third Quarter 2022 Financial Results
7:00am
DEF 14A
82alz7mjz9uky4x2
29 Apr 22
Definitive proxy
7:01am
10-K
m7efb5 7idna
14 Mar 22
Annual report
7:04am
S-1
EX-10.3
290i1
28 May 21
IPO registration
4:04pm
S-1
EX-10.17
3b3vnw2pvc17r0hm2
28 May 21
IPO registration
4:04pm
DRS
EX-10.3
kb1 r1vde
16 Apr 21
Draft registration statement
12:00am
- Prev
- 1
- Next